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This report aims to summarise the currently available evidence and knowledge around 
IPED use, examine the challenges faced by drug service providers working with IPED 
users, and look at how we can better work with this group. 
 
This information in this report is drawn from third party academic research, reports from other 
professional organisations in the field, primary data from government sources (where available), 
and the expertise and professional experience of our own staff. All third party information and 
sources have been referenced where used.  
 
Research and design by Louis Richards, Lifeline Project 
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Executive Summary 
 
• IPEDs are substances used to alter or enhance or alter a person’s appearance or 
abilities. The most prominent are anabolic steroids, ‘smart drugs’, and skin-
enhancement drugs (for example Botox). 
 
• Evidence is fairly thin on prevalence and impact of all three groups of 
substances, though use appears to be growing. 
 
• Most IPEDs are self-prescribed and administered by users without medical guidance. 
Substances themselves tend to be produced and sold without the legal regulation or 
safeguards that would usually surround most medicines. 
 
• IPED use has traditionally been seen as outside of drug services’ remit and 
most IPED users unlikely to view themselves drug users in the traditional sense. 
 
• There are comparable numbers of injecting steroid users and injecting heroin users in 
England, with some reports indicating up to 300,000 injecting steroid users. Numbers 
injecting cosmetic drugs such as Botox are likely even higher. 
 
• The most significant risks to steroid and Botox users are around injecting. Rate 
of HIV amongst steroid users are approximately the same as amongst heroin users. 
There is great need for safer injecting advice and needle exchange amongst these 
groups.  
 
• Aside from risks related to injecting, illicit steroid use also risks liver damage, kidney 
damage, cardiovascular issues, dependency, depression, insomnia, and unwanted 
changes to sexual characteristics (eg breast growth, hair loss, or impotence). 
 
• There is a strong community around steroid use within gyms and online, and similarly 
a strong online community around smart drugs. Personal experience and word of 
mouth in these contexts is the usual source of dosing and usage guidance and 
information on health risks.  
 
• Steroid users themselves are likely to be more knowledgeable on how different gym-
drugs work and interact than drugs workers or other professionals due to the vast 
range of substances often used. Unless a worker is an experienced IPED user, 
they are unlikely to be able to give substance-specific guidance or advice. 
 
• Aside from the strongest substances (such as amphetamines or methylphenidate), 
most smart drugs have little to no significant negative impact on users. 
 
• Building on personal qualities such as self-acceptance, positive self-image, or 
stress-management may help those with dependent or problematic IPED use, 
though we should be careful not to stigmatise all IPED use – the desire to 
improve oneself is not unusual and not all IPED use is necessarily harmful. 
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What are IPEDs? 
 
Image and Performance Enhancing Drugs (also known as IPEDs, PIEDs, SEIDs, or human 
enhancement drugs) are substances used with the intention of altering or improve a 
person’s appearance or abilities. This could include improving athletic performance, academic 
performance, sexual performance, altering skin tone, losing fat, reducing wrinkles, or increasing 
muscle mass. IPEDs tend to be self-administered by users without medical supervision or 
guidance, and the substances themselves produced and sold without proper regulation or 
safeguards (Evans-Brown et al 2012). 
 
IPED use is often separated from use of other drugs, with IPED users typically not viewing 
themselves as drug users and being viewed as outside of the remit of traditional drug 
services. Despite this, there is a significantly sized population regularly using IPEDs across 
England. There are concerns around the long- and short-term health effects of these substances 
and the practices related to their use (such as injecting) that make them important for health and 
social care services to consider.  
 
IPEDs are most commonly discussed in the context of anabolic steroid use, however there are a 
range of substances that may come under the heading of ‘IPEDs’. For the purposes of this report 
these shall broadly be separated into three categories: 
 
• Steroids and gym-drugs1 
• Nootropics (AKA ‘smart drugs’ or ‘study drugs’) 
• Botox, dermal fillers, and tanning drugs 
 
Various other substances such as diet/weight loss pills or drugs intended to improve sexual 
performance (including those used in chemsex) could also come under the heading of ‘IPEDs’, 
but shall not be discussed in this document. Similarly, there are many other practices not 
involving substance use that include similar motivations and health risks (for example home 
tattooing/body modification or extreme dieting), however these also will not be discussed here. 
Nevertheless, many issues and point raised in this document could carry across to these 
contexts. 
 
Due to the cultural distinction between IPED users and psychoactive drug users, IPED users 
receive little focus from traditional drug services, little support or advice around use, and may be 
hard to engage with health services. Public discourse on anabolic steroids and nootropics in 
particular often focuses more heavily on whether IPED use is fair or ethically justifiable rather 
than any potential health implications. Despite this, many of the substances used and 
practices around IPED use are essentially similar to traditional psychoactive drugs and 
hold comparable health risks.  
 
Steroids and gym-drugs in particular have become the subject of increased public debate in 
recent years due to a series of high profile sports doping scandals, including those around cyclist 
Lance Armstrong and Russia’s Olympic team. Often these debates focus around the fairness of 
IPED use in athletic competition or academic achievements and little consideration is given to the 
health effects on users themselves. 
 
 
																																																								
1 ‘Gym-drugs’ is not a recognised term in the wider literature, rather a short-hand term used here 
due to the vast range of different hormones, steroids, and other supplements used together in the 
gym context in addition to anabolic steroids. 
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Steroids and Gym-Drugs 
What are steroids and gym-drugs? 
 
Steroids and gym-drugs include a wide range of steroids, peptides, hormones, and other 
supplements used by a certain subsection of – typically male – gym users and body 
builders. Anabolic-androgenic steroids are the most well-known and widest used of these 
substances, however all are common amongst this group and used with similar intentions for 
similar effects on the body. In common discourse these substances are more often simply 
referred to as ‘steroids’ or ‘IPEDs’, however the term ‘steroids and gym-drugs’ is used here to 
distinguish from other very different IPEDs such as nootropics and to include other non-steroid 
image-enhancement substances regularly used in the same context by the same group. 
 
Regular IPED users of this type tend to follow complex regimens using a ‘stack’ of various 
differing substances, making it difficult to give an exhaustive breakdown of all types and effects 
here - the World Anti-Doping Agency’s list of banned substances alone names 70+ different 
anabolic steroids, 40+ peptides and related hormones, 20+ metabolic modulators, and 20+ 
diuretics and masking agents (WADA 2016). Users usually stack an average of three different 
substances at a time and use in cycles of between 4-12 weeks ‘on-cycle’ (with 8 weeks cited 
as a common average) and short break ‘off-cycle’ (Brennan et al 2016). Users may employ 
different stacks at different points during each cycle to maximise desired effects or manage 
unwanted side effects. 
Who uses steroids and gym-drugs? 
 
Overall prevalence of IPED use amongst the general adult population is relatively low, at 
up to around 100,000 current users nationally by most estimates, with estimates of lifetime use 
ranging up to 300,000 thousand (Home Office 2016, McVeigh et al 2015). Nevertheless, this is 
still a significantly sized population and much higher than estimated prevalence of injecting 
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heroin use, for which the benefits of harm reductions are clear. Across Merseyside and 
Cheshire just under 5,500 people who accessed needle exchange services in 2014/15 were 
IPED users (around 57% of those who disclosed their primary substance (Whitfield et al 
2015) – though there is high year-by-year variability in this figure with 77% reporting IPED use in 
the previous year). 
 
Due to a lack of engagement with traditional drug services and gaps in other reporting systems, 
precise prevalence and demographic information on these substances is very thin. 
NDTMS does not record IPEDs as separate substances and needle exchanges have no 
mandatory national reporting system meaning there is no systematically collected national 
information even on steroid users that do engage with drug services. Most prevalence data 
available is based on isolated studies and opt-in reporting schemes – although there are 
nevertheless some scientifically rigorous studies (reviewed in Brennan et al 2016), and robust 
opt-in reporting schemes in some regions (for example the Integrated Monitoring System for 
Cheshire and Merseyside referenced above (Whitfield et al 2015)). 
 
There is little research on differences in prevalence between ethnic communities or other cultural 
groups, although use has been identified across a range wide of ethnicities, nationalities, and 
within the LGBT community (Brennan et al 2016). 
Gender and Motivation 
Steroid and gym-drug users are typically male body builders who use these substances to 
increase muscle mass and definition, however female users are not unheard of and numbers 
are increasing with the growth of female body building as a sport. IPEDs of this type may also be 
used to increase sports performance, however whilst use in sports is far more publicised, this 
group is much smaller than those using steroids and gym-drugs to build muscle; performance 
enhancement is significantly less often cited as a motivation compared to improving appearance 
(Brennan et al 2016). 
 
Some users may also aim to build muscle and strength for occupational reasons due to 
working in highly physical jobs where strength and size are required (ranging from security 
to illicit drug dealing), however this is also less often cited as a motivation and based more on 
anecdotal evidence than published research (Evans-Brown 2012). 
 
Melanotan is the main exception amongst substances of this type as it does not alter 
muscle definition or size. Melanotan is used to darken skin tone as an alternative to fake tan 
amongst body-builders as it does not streak or interact with anything else put on the skin. This 
substance is grouped with steroids and other gym-drugs here despite its very different 
effects as it very common amongst the same demographic and is also injected. 
Furthermore, surveys have found however that there may be some confusion around the effect of 
melanotan for steroid users, with a significant number of those that used melanotan not reporting 
its effect on skin colour as a motivation, despite this being its most significant effect (Bates & 
McVeigh 2016). This may be as it is used as part of complex combinations of IPEDs where other 
users anecdotally report a perceived benefit. 
Age 
The largest and most recent UK-wide survey of IPED users found that first time gym-drug is 
almost always under the age of 30, usually in early 20s. Whilst a small proportion of those 
surveyed cited first use under 18 (6.1%), first use under 16 was very rare (0.6%) (Bates & 
McVeigh 2016). Average age of IPED users found in several studies to be approximately 27 
(Brennan et al 2016). Anabolic steroids are one of only a small handful of illicit drugs where 
prevalence is lower amongst young adults (0.1% amongst 16-24) compared to all adults 
(0.5% amongst 16-59) (Home Office 2016). The only other substances where this is the case are 
heroin and crack cocaine. 
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What are the effects and risks? 
Physical and Mental Health 
Anabolic steroids can have a range of unwanted side effects including increased 
aggression and anger (“roid rage”), mood swings, and unwanted physical changes. Due to 
anabolic steroids’ similar action to testosterone, most of these physical changes are around 
gender-specific features – for example, shrinking testicles, growth or breast tissue, hair loss, 
and erectile dysfunction in men, and clitoral enlargement, shrinking breasts, and masculinisation 
of facial features in women. 
 
Long-term use has also been associated with liver damage, kidney damage, and 
cardiovascular issues such as high blood pressure and in some cases cardiac arrest (Bates & 
McVeigh 2016). Melanotan has been associated with similar risks to the cardiovascular system 
as well as possible indications of skin cancer (Evans-Brown 2009). 
 
Poly-pharming with other substances in a ‘stack’ is often used to manage negative side-
effects of use, but potential interaction between substances can also increase risk and 
unpredictability (Brennan et al 2016). 
 
Examining scientific studies on the risks of specific substances however can be sometimes 
misleading – the health risks of many IPEDs are due to those substances being mislabelled, sold 
as something else, or due to adulterants not listed (Evans-Brown et al 2012). Whilst there are few 
examples of widespread serious harm as a result of counterfeit products sold in the UK, there are 
examples of serious harm (including many deaths) globally (ibid.). 
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Injecting Risks 
Whilst the above issues are a concern, the main risks around IPEDs are those related to 
injecting2. Although not all IPED users inject, this is the most common route of use for most 
(86% of IPED users inject, 76% cite oral use, and 65% use both methods (Bates & McVeigh 
2016)). Generally speaking, IPED users are more likely to use oral substances in first-time use 
before progressing to injecting (Bates & McVeigh 2016). 
 
As with any other injecting drug use, there are risks around: 
 
• BBV (including Hepatitis and HIV) 
• Damage to veins and arteries 
• Infection at injecting sites 
 
IPED users are most likely to inject intramuscularly, as opposed to subcutaneously or 
intravenously, and most frequently in the gluteus, quadriceps, or deltoids (Bates & McVeigh 
2016).  
 
Whilst unlikely to view themselves as drug users or engage with drug treatment services, 
evidence appears to indicate that it is not uncommon for steroid users to access needle 
exchange services. As mentioned earlier in this report, around 57% of people accessing 
needle exchanges across Merseyside and Cheshire in 2014/15 were doing so for steroid 
use (Whitfield et al 2015). According to the largest and most recent survey of UK IPED users, 
65% reported having used a needle exchange in the last 12 months – though due to 
sampling biases in this data, this number may be higher than actual rates (Bates & McVeigh 
2016). Only a small number report sharing needles (1.5-9% depending on study), however 
around 10% reuse needles (Bates & McVeigh 2016, Hope et al 2013).  
 
Some health risks associated with injecting will be of less concern than amongst other injecting 
drug users (primarily heroin users) due to differences in other social circumstances. Traditional 
injecting drug users are far more likely to face a range of other social and health issues such as 
homelessness and unemployment (Whitfield et al 2015), which puts them at greater risk of health 
problems more generally. Despite this, the most serious risks around injecting including spread of 
BBV are comparable. Rates of HIV infection are roughly equivalent to injecting 
psychoactive drug users (1.5% of users), and Hepatitis B & C infection slightly lower than 
injecting psychoactive drug users though still significantly higher than national averages 
(Bates & McVeigh 2016). 
 
One significant difference between steroid users and other drugs users that makes injecting 
steroid use of particular concern however, is that whilst injecting is fairly unusual amongst casual 
psychoactive drug users, limited for the most part is limited to the harder core of heroin users, 
injecting is the most common route of use for steroid users of all levels (although users 
generally begin by using orally). Whilst safer injecting advice would not be required for 
most psychoactive drug users, even fairly casual steroid users would likely require this 
advice. 
Risk of Dependency 
Whilst there is evidence of risk of developing addiction and withdrawal symptoms when 
stopping use of steroids and gym-drugs, this is not mentioned or examined in any detail in 
the literature. Most steroid and gym-drug users use these substances in cycles, alternating 
periods of regular use with periods of abstinence, possibly indicating that users are aware of the 
risk of physical dependency and generally speaking are able to break use voluntarily (at least 																																																								2 Although it should be noted that risk of liver damage is much higher with long-term oral use of 
steroids than injected steroids.	
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temporarily). Despite this, some studies have noted risk of depression and insomnia 
amongst steroid and gym-drug users, in particular during breaks between cycles (Brennan 
et al 2016). That these symptoms (in particular insomnia) manifest during breaks in use may 
indicate that they are associated with withdrawal. 
 
It is possible that little of the literature focuses on dependency or addiction due to the fact that 
steroids and gym-drugs have no immediate psychoactive effects caused directly by these 
substances (Brennan et al 2016). As a result heavy users will not experience or exhibit signs 
of intoxication and even if heavily dependent could continue to maintain fairly normal day-
to-day routines. 
 
Lack of psychoactive effect also means that common screening tools used for other drug 
dependencies are not appropriate and would not identify steroid dependency (Brennan et 
al 2016). Despite this, many behaviours of heavy users such as the amount of time and money 
committed to use, continued use at evident detriment to their own health, and judgment of self-
worth on the results of use would seem to point towards some level of psychological 
dependence. As IPEDs are not recorded as a separate category of drug by NDTMS, it is not 
possible to estimate prevalence of steroid or gym-drug dependency amongst those seeking drug 
treatment or support. 
Poly-use with psychoactive drugs 
Significantly higher than average numbers of IPED users report having used other 
recreational drugs in the last year (32% compared to 8.4% national average (Bates & McVeigh 
2016, Home Office 2016)). In line with national trends, cannabis was the most commonly used 
illicit recreational drug, however reported use of powder cocaine was much higher 
(prevalence estimates ranging from 22-46% depending on the study compared to 2.2% 
amongst the general population (Bates & McVeigh 2016, Home Office 2016). Reported 
ecstasy and amphetamine use was also higher than national averages, though considerably 
lower than rates of use than cocaine and cannabis. Similarly rates of ever having injecting 
psychoactive substances were significantly higher than national rates, however still only a very 
small minority (Hope et al 2013) 
 
Combined use with cocaine and alcohol can put additional strain on the liver. Poly-use 
with stimulants may place additional strain on the heart and increase cardiovascular risks. 
Research on poly-use does not indicate whether gym-drugs and stimulants are used 
simultaneously to increase performance or whether this demographic are simply more likely to 
use stimulants recreationally independently of their IPED use. Cardiovascular risk is likely to be 
much higher if these stimulants are being used during exercise or to supplement their IPED use. 
What is the law around steroids and gym drugs? 
 
Those steroids and gym-drugs that are specifically classified under the Misuse of Drugs 
Act (primarily anabolic steroids) are generally Class C. Most of these are legal to possess 
for personal use, however importing/exporting and possession with intent to supply can 
carry up to 14 years in prison and an unlimited fine for supply. 
 
Many steroids and gym-drugs (including anabolic steroids) also have medical applications, 
meaning they may in some cases be legally prescribed or obtained with a prescription. This may 
indicate the possibility of a black-market dealing in redirected prescribed medication, however 
there is little evidence that this is the case and most substances appear to be illicitly mass-
produced and imported from abroad rather than legally obtained and redirected (Bates & 
McVeigh 2016). Users primarily obtain these substances either online or from dealers in 
gyms. Dealers are usually IPED users heavily embedded in the gym culture themselves 
funding their own IPED use (Van de Ven 2016). 
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NICE guidance recommends sharps bins or even needle exchange facilities in gyms (NICE 
2014), however gyms can be cautious to avoid appearing to condone or accept steroid use due 
to the possibility of negative publicity and legal issues. Whilst gyms have a duty of care towards 
their customers, this duty of care could be interpreted either way between zero-tolerance towards 
steroid use or the need to provide harm reduction. It is unlikely gyms could argue that such 
obligations would extend to permitting dealing however. 
 
Aside from increased aggression and mood swings associated with long-tem use and the 
psychological aspects of dependency (for those that develop a dependency), steroids and other 
gym-drugs have no notable direct psychoactive effects. Consequently, they should not be 
affected by the Psychoactive Substances Act 2016, and only carry legal risks is 
specifically proscribed under the Misuse of Drugs Acts 1971. Despite this, there is some 
evidence that some online retailers use similar methods to NPS retailers to circumvent legal 
restrictions, advertising products as ‘not for human consumption’ or as ‘research chemicals’ 
(Evans-Brown et al 2012, Brennan et al 2016). 
How should we work with steroid and gym-drug users? 
 
There is a staggering range of different substances used by this group in addition to 
anabolic-androgenic steroids. Steroid and gym-drug users tend to have quite complex 
regimens based on the guidance of more experienced IPED users and employ a variety of 
different substances simultaneously either to boost effects or mitigate side-effects (also known as 
‘stacking’ or using a ‘stack’). This makes it particularly difficult for the typical healthcare 
practitioner or needle exchange worker to give precise harm reduction advice around specific 
substances. Indeed, attempting to give advice or information on substances to users with 
likely far greater knowledge is more likely to undermine trust and engagement than help. 
One study found that 40% of steroid users trusted their dealer’s advice better than any 
doctor’s (Brennan et al 2016). 
 
Despite this, there are some broad pieces of advice on usage that can be given with little 
knowledge of the substances themselves: 
 
• Aim at shorter cycles of use and longer breaks between cycles 
 
• Beware of counterfeit or unknown substances – don’t inject a substance if you 
have any doubt about what it is 
 
• Avoid poly-pharming as far as possible – the higher number of substances you 
use concurrently the more unpredictable the effects 
 
• Start small and be aware of individual differences and built tolerances – don’t 
adopt a more experienced user’s regimen until you have experience and 
awareness of your own limits and needs 
 
• If experiencing negative or unexpected side effects, seek medical advice 
 
• Don’t neglect your other health needs, especially keeping up a healthy diet 
(which may need to be much higher calorie than usual) 
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Needle exchange workers are in a much better position to give advice on safer injecting, 
equipment use, and wound care rather than advice on how to use the substances 
themselves. Whilst steroid and gym drug users will likely have significantly more knowledge on 
the substances themselves (or at least, believe themselves to have better knowledge), 
knowledge of safer and clean injecting is much less common. 
 
Injecting advice given to steroid users should include all usual information around safer injecting 
that would be given to others accessing needle exchange, including: 
 
• Do not reuse or share equipment 
 
• Keep injecting sites clean 
 
• Keep equipment sterile 
 
 
And more specifically to steroids and gym-drugs rather than other drugs: 
 
• Avoid veins or arteries and inject intramuscularly (into muscle). Do not inject 
intravenously. 
 
• Quads and glutes are best and least painful injecting sites (injecting into 
specific muscles you want to grow doesn’t work, substances need to processed 
via the liver first) 
 
• Safe injecting is preferable to oral use – whilst there are many risks to injecting, 
generally speaking injected steroids have lower risks of other harms in the long-
term than oral steroids. 
 
 
Uptake of Hep B vaccination and testing for Hep C or HIV is much lower amongst IPED users 
than those who inject psychoactive drugs (PHE 2016). Needle exchange also offers ideal setting 
for health checks and BBV screening. 
 
Many needle exchange users will want to enter and exit as quickly as possible, however needle 
exchange is also a useful opportunity for interaction to encourage safer practices, provide other 
health assessments, broach other issues, or engage users in other services. Such efforts should 
be approached with a light touch however, and as always harm reduction is first priority – if 
someone engaging with needle exchange has no interest or desire to engage with or 
discuss other issues this should not be a barrier to their accessing clean injecting 
equipment.  
Motivations for Use 
We should be aware that not all steroid and gym-drug users will be using dependently or 
due to psychological issues such as body dysmorphia (although body builders in particular 
may (Brennan et al 2016)) – aiming to improve appearance or physical ability is not necessarily 
unusual or dysfunctional, and being strong and large as a masculine ideal is a fairly widespread 
cultural phenomenon. Enhancing one’s physical appearance or abilities is neither a new nor 
unusual goal (Evans-Brown 2012). 
 
Although use of image-enhancing substances is clearly closely tied to issues of self-
perception, cultural physical ideals, and social pressures, we should not patronise or 
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insult IPED users by focusing on these issues, assuming that they have poor self-worth, 
or that they only use due to social pressures. 
 
Whilst considering motivations and patterns of behaviour is useful in tackling problematic 
use, it is better to first look at the impact of user’s consumption on their life rather than 
speculating at their motivations or imposing your own norms of healthy behaviour onto 
users. Nevertheless, if someone is spending disproportionately large amounts of time and money 
using these substances, using to the serious detriment of their social life or health, or feels 
compelled to continue using despite feeling that their use is having a negative impact on their life, 
it would be important to then work with the user on their reasons for use, including their self-worth 
and self-image. 
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Nootropics (Smart Drugs) 
What are nootropics? 
 
Nootropics (AKA smart drugs, study drugs, cognitive enhancers, or neuroenhancement 
drugs) are a range of substances used most commonly by students to boost mental 
performance, concentration, or alertness3. Type and effect can vary, with substances ranging 
from mineral supplements aimed to boost brain functioning to stronger stimulants such as 
amphetamines and phenethalymines. Milder stimulants such as energy drinks or caffeine pills 
could also be included under this heading if used for similar reasons. 
 
The most popular UK brands (aside from milder supplements) are: 
 
• Provigil (Modafinil) 
• Ritalin (Methylphenidate) 
• Adderall (Amphetamine) 
 
There is very little research on use of smart drugs, so a significant amount of information 
available is based on speculation, folk knowledge, and anecdotal evidence rather than scientific 
research.  
Who uses nootropics? 
 
Nootropics may be used to increase cognitive functioning and focus in any field of work, but as 
their other common names (study drugs or smart drugs) imply, it is academic study that is 
popularly seen as the primary motivation with use most widespread amongst university 
students. 
 
Despite occasional alarmist reporting from mainstream news sources, smart drug use does not 
appear to be widespread even within the student population. Limited studies available 
estimate that between 3-10% of students have used nootropics (excluding caffeine), but 
only a very small proportion of these used regularly, with most using only around exams 
and coming up to deadlines (Deline et al 2014, Singh et al 2014). The substantial majority of 
UK students reported being both unaware and uninterested in nootropics (Singh et al 2014). 
Despite this, a large proportion (approx. 30% of students) reported having used caffeine for 
cognitive enhancement (ibid.). 
 
Use by students may be motivated simply by a personal desire to perform better academically, 
but this is often reported to be due to high pressure and expectations from family, peers, or 
society at large. Increase in financial pressures on students in recent years due to changing 
university fees and bursaries may also lead students to feel greater pressure to perform well and 
achieve higher level qualifications (to get ‘value for money’). 
 																																																								
3	Many of these substances also have medical applications and the same term (nootropics) may 
also be used in the other contexts to refer to drugs used to treat Alzheimer’s, strokes, ADHD, or 
schizophrenia.	
Nootropics are usually bought in bulk directly from legal online retailers rather 
than via street dealers or other users, often following the guidance or 
recommendation of more experienced users in the online nootropic community 
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Outside of the academic setting nootropics may also be used by those in high-pressure 
jobs or those that require long periods of concentration or alertness – for example there are 
cultural stereotypes of heavy cocaine use amongst those working in the finance sector where 
aggression and working long working hours are desirable, or use of stimulants by long-haul 
drivers to keep awake. Unfortunately, there is little to no evidence or research around these types 
of use and this remains speculation and stereotype. 
 
If we include use of caffeine to improve concentration and alertness more widely (whether 
in hot drinks, energy drinks, or pills), prevalence rates will undoubtedly be very high 
amongst the general population and across most demographics. There are both advantages 
and disadvantages to this approach to the topic of nootropics: 
 
• Understanding how widespread and common it is to use drugs to improve mental 
performance can de-stigmatise and de-mystify the topic, helping us understand empathise 
with users’ experiences and motivation 
 
• However by focusing on caffeine we may lose sight of higher risk patterns of use and very 
specific demographics and subcultures most involved in nootropic use 
 
Consequently, whilst caffeine use will be considered in this report, it will be only in the context of 
use by groups more likely to also use other nootropics (for example students). Nevertheless we 
should bear in mind that substance use to improve focus, alertness, and concentration is 
not unusual or necessarily dysfunctional. 
What are the effects and risks? 
 
As there are a wide range of substances may come under the heading of ‘nootropics’, we must 
not assume that there are the same degree of risks with all. Whilst some substances used in 
this way are stimulants with comparable effects and risks to recreational street drugs (for 
example Adderall – although this particular brand is less popular in the UK), others are far 
more similar to food supplements and have little to no significant negative impacts. 
 
When speaking of risks it is therefore useful to separate nootropics into three broad categories: 
 
1. Supplements & non-psychoactive substances – for example vitamin supplements, 
magnesium pills, or racetams 
 
Generally speaking these substances have little notable psychoactive effect and are 
intended to work rather by stimulating healthy nerve growth and neurological functioning. 
As with most substances, taken in significant enough volumes these substances can have 
adverse side effects including acute toxicity, however there is widespread anecdotal 
evidence of regular moderate use without any adverse effects or risk of 
dependency and most are freely sold as food supplements or mild medicines. Piracetam 
(the most common nootropic racetam) can have mild side effects such as insomnia or 
anxiety, but such effects are generally rare, minor, and short-lived (Koskiniemi 1998). 
 
It should be noted however that due to less stringent regulation of herbal supplements 
compared to registered pharmaceuticals, the fact that a substance is being sold as a 
herbal supplement does not necessarily guarantee that it has lower risks than other 
substances, especially if bought online from less regulated markets abroad (Evans-Brown 
2012). 
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2. Mildly psychoactive substances – for example modafinil or caffeine 
 
Most of these substances would be more accurately described as having adverse side 
effects than carrying serious health risks. As they function similarly to stimulants, most 
side effects of heavy use mirror stronger stimulants – for example irritability, 
disturbed sleep patterns, anxiety, raised heart rate, jaw-clenching, or difficulty 
concentrating after use. As with any stimulants, boosts to functioning are only 
temporary and users will eventually crash. Nevertheless, side effects are still 
reportedly fairly mild and there is little evidence of long-term risk. There is limited 
evidence that heavy modafinil use may be linked to some skin conditions and psychiatric 
health issues, but evidence on this is still thin (Evans-Brown 2012). 
 
Whilst cases of modafinil dependency have been reported, they are very rare (USFDA 
2015). Caffeine dependency is of course also possible, but aside from irritability and jitters 
it is unusual for this to have significant impact on users’ lives. 
 
3. Stronger stimulants – for example Adderall (amphetamine), Ritalin (methylphenidate), 
and cocaine 
 
Methylphenidate (Ritalin) carries some risk of dependency, though this is reported as 
fairly rare unless being used heavily (Evans-Brown 2012, Morton & Stockton 2000). Risk 
of developing dependency from recreational cocaine and amphetamine use is well 
established, but it is not clear whether this is likely to occur based on the levels of 
use amongst smart drug users (as most use only occasionally, mostly around exams 
and deadlines (Singh et al 2014)). Nevertheless, amphetamines and cocaine use carries 
well-established and notable health risks – all side effects mentioned above will likely be 
stronger and there are longer-term risks around strain on the liver, kidneys, and 
cardiovascular systems. The more intense psychoactive effects of these stimulants also 
place users are much higher risk of behaving dangerously or irresponsibly compared to 
milder nootropics. 
 
From the above list we can see that whist there are health risks to nootropic use, unless using 
heavily, regularly, or using stronger stimulants users are unlikely to encounter any 
significant health issues or develop any kind of dependency. Nevertheless, there are a few 
points users should bear in mind: 
 
• Use of any medicines or drugs not under medical direction will always carry 
some degree of risk, especially widely untested and unregulated substances 
like many nootropics. Whilst this risk is low at the milder end of the scale (such 
as food supplements), if using extensively users should make sure to consult their 
doctor and monitor on any adverse side-effects.  
 
• These substances rarely make users able to better or clearer, rather simply 
able to temporarily work longer. As with caffeine or sugar, boosts cannot be 
maintained indefinitely and users will usually eventually crash and experience 
more difficulty thinking or sleeping afterwards. 
 
• When buying substances online, counterfeit or mislabelled substances can 
be a risk if using disreputable sources. The strong online community around 
nootropics to some extent counteracts this by sharing recommendations and 
warnings, though not all users will be a part of this community. 
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What is the law around nootropics? 
 
Legal status of nootropics vary by substance. Some popular brands such as Ritalin 
(methylphenidate) and Adderall (amphetamine) are both Class B drugs under the Misuse of 
Drugs Act 1971, however most are not specifically classified. This is in part as many are not sold 
as regulated medicines (Evans-Brown 2012). Those that are classified substances are less likely 
to be sold openly online, although possibly may be sold on the dark web – though due to the 
covert nature of the dark web this is hard to verify. 
 
Despite this, any nootropics not previously criminalised under the Misuse of Drugs Act 
1971 may also now have legal restrictions under the Psychoactive Substances Act 2016. 
Users should bear in mind that even if not previously specifically classified substances, if study 
drugs have any psychoactive effect (as they should do if they work as intended) then selling on or 
even giving away these substances can result in up to 7 years in prison (although personal 
possession would not be illegal). There are complications to this law however as many smart 
drugs are licensed as medicines or food supplements which would exempt them from the 
Psychoactive Substances Act in some contexts. 
 
There is evidence that the introduction of the Psychoactive Substances Act has already had an 
impact on the nootropics trade, with at least one prominent nootropics website having had to 
significantly cut their business. 
Source: https://twitter.com/SNootropicsUK 
 
In light of these recent legal issues, users should take caution when buying these substances 
online. Even if buying only for personal use, if buying from anywhere where the substances 
are shipped to the UK from abroad, the buyer could be charged with importing a 
psychoactive substance (a charge also carrying up to 7 years in prison).4 
																																																								
4  Despite these legal issues and the voluntary closure of some retailers, to the author’s 
knowledge there have been no prosecutions to date for sale of nootropics under the 
Psychoactive Substances Act. There is significant debate around the enforceability of the act, 
including the definition and possibility of demonstrating ‘psychoactivity’, although further 
exploration of how this may impact the nootropic market is beyond the scope of this document.  
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Source: http://www.smartnootropics.co.uk/the-psychoactive-substances-act-2016/ 
[Whilst this website is still live as of Septmeber 2016, social media posts indicate Psychoactive 
Substances Act may have has a significant impact on its future] 
 
Many nootropics also have medical applications for conditions such as in treating ADHD and are 
in some cases prescribed, however possession of any such substances without a prescription 
would be considered the same as possession of any other illicit drug. It is likely there is a black 
market trade in re-directed prescription medication, but little firm evidence on the scale or 
reach of this market (Evans-Brown 2012). 
How can we work with nootropic users? 
 
In light of the limited evidence around prevalence of nootropic use in the UK, it is important to 
bear in mind that high-risk or dependent use of these substances appears to be fairly rare, 
and thus attempting to engage users with traditional drug treatment services or taking a 
position of hard abstinence may not be appropriate. Most users will not be suitable for 
engagement with drug treatment services and require only nudges toward safe use and 
harm reduction education. 
 
There is currently a gap in good quality advice and health information on nootropics for 
younger people. Despite younger people and students appearing to be the primary market for 
nootropics, it is interesting to note that at the time of writing Talk to Frank, the government’s 
official drugs information site primarily geared at adolescents and young adults, has no 
information on study drugs at all (Ritalin is mentioned in passing, but not in the context of 
smart drugs). There are strong active online communities centred around nootropic use which are 
a major source of information for heavier/more involved users; signposting to such sources may 
be a useful resource for harm reduction advice for casual users in the absence of any other 
resources from health authorities. 
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If students are feeling the need to use smart drugs due to high levels of stress or 
pressure, mental health and general wellbeing would be an important target for 
interventions. For example it may be useful to provide support with coping skills, dealing with 
stress, time management, or self-confidence. 
 
Exam season in particular may be a useful time to target students due to higher levels of 
stress and pressure at this time. Health services covering areas with large educational 
establishments such as universities or colleges may be advised to identify what time of year 
deadlines or exams are due and provide harm reduction or stress management advice in the 
preceding weeks. 
 
For other users than students (for example those in high pressure employment or with 
excessively long working hours), it may be useful to offer advice on employment rights, 
educate employers on the health and financial benefits of properly supporting and not 
overworking their staff, or offering users employment skills to retrain for jobs with less 
pressure or shorter working hours. Given the very thin evidence on users of this group 
however, it would be difficult to know where to target these approaches or even who to target. 
 
Another possible approach if wishing to discourage use is simply to emphasise that the available 
evidence is very inconclusive on whether smart drugs actually offer any significant effect at all on 
cognitive functioning or academic performance, especially in the longer term. As discussed 
earlier, most mild substances have very little effect, and those that do generally only offer short-
term boosts, often at the expense of mental functioning later (Evans-Brown 2012). Rather than 
preaching the health concerns of nootropic use, it may be a more convincing approach to target 
users’ pragmatic side and question whether nootropic use would actually have any impact. It 
could be argued however that this approach would be self-undermining – if people should not use 
these substances as they have little effect, why are we concerned with advising people not to use 
them? The evidence is thin both on whether they have any significant effect on mental functioning 
and whether they have any significant health impact. 
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Botox and Tanning Drugs 
What are these substances and who uses them? 
 
• Botox & dermal fillers – Botulinum toxin (Botox) is the most well-known cosmetic 
injectable and is often used as a short-hand term for all dermal fillers and line-smoothing 
agents used to make the face appear younger and reduce the appearance of wrinkles 
(although ‘Botox’ technically refers to only that specific substance, botulinum toxin). There 
are also a wide range of other unregulated dermal fillers and injectables used for the 
same aim that work by filling the area under the skin rather than paralysing the muscles 
(Collagen being the most prominent example) (DoH 2013). 
These substances are used primarily by women for aesthetic reasons. 
 
• Melanotan – this is injected to darken skin tone with the aim of developing a tan or 
‘healthy glow’. Unlike Botox or Collagen, this doesn’t need to be injected into the specific 
area were the effect is desired, darkening occurs across the body. 
Melanotan is used most commonly by body-builders along with steroids and other 
gym-drugs (see earlier section), however there are reports of these substances also 
being used by women as an alternative to tanning beds (Evans-Brown 2009). 
 
There are unfortunately no statistics on the prevalence of cosmetic injectables, however 
increasing numbers are seeking cosmetic treatment, with around 51,000 people in the UK 
currently having cosmetic surgery each year, around 90% of whom are female (BAAPS 
2015). Number of people who use cosmetic injections such as Botox is likely significantly 
higher than this number due to surgical procedures being significantly more expensive and 
invasive than injectables. The UK department of health estimates that around 90% of cosmetic 
procedures are non-surgical (DoH 2013).  Some news reports estimate that millions of people 
inject these substances each year (significantly higher than rates of psychoactive drug injecting), 
but such such reports are generally based on speculation rather than any firm evidence of 
prevalence. 
 
 
Skin-Bleaching Creams 
Aside from the injectables listed above, there are also reports of a growing market in skin-
lightening or skin-bleaching creams, used primarily by women of Black African, Afro-
Carribean and or Asian ethnic backgrounds to give whiter or lighter skin (Evans-Brown 
2012, The Parliamentary Office of Science and Technology 2013). 
 
Setting aside the clearly problematic social and racial undercurrents that underpin the desire for 
dark-skinned women to appear whiter, such creams can also pose certain health risks. 
Historically the dangers of such creams has come from their frequently high mercury content 
which can cause kidney damage in the long-term, as well as irritation and scarring to the 
applied areas (WHO 2011). Whilst mercury content is still a risk in these products (and there 
have been cases of mercury poisoning from these products in the UK in the recent past (Evans-
Brown 2012)), there are also health concerns around unlicensed sale of the substance 
hydroquinone. Hydroquinone is an untested and unregulated product not licensed for use in 
cosmetic products which can cause irritation and damage to the skin (Evans-Brown 2012). 
Whilst there are medically certified skin-bleaching creams prescribed for certain conditions, these 
are not legally freely available and not licensed for cosmetic use. 
 
Evidence on use of this group of substances is still thin but is predicted by some sources 
to likely become an increasing public health concern amongst certain demographics.  
	18 IMAGE AND PERFORMANCE ENHANCING DRUGS (IPEDS) 	
What are the risks? 
 
If administered safely by a trained medical professional there is in fact very little risk to 
Botox injections or most other common licensed injectables (Cohen et al 2009). 
Unfortunately, currently in England no certification or qualification is required to administer 
these substances5, there are many untested substitute substances sold with unknown 
risks, and there is are increasing reports of cosmetic injections being administered at 
home (Evans-Brown 2009). 
 
Consequently, the main risks to users from cosmetic injectables are around unsafe injecting, for 
example: 
 
• Damage at injecting sites (facial injecting being of particular concern due to risk of 
accidentally hitting nerves, which can result damage such as drooping facial features) 
• Blood-Borne Viruses 
• Toxicity from counterfeit or mis-dosed substances 
• Infection or inflammation at injecting sites (in particular if using counterfeit or unknown 
substances which the body may react strongly to) 
 
Cosmetic use of Botox and dermal fillers has only reasonably recently become widespread, so 
long-term effects are not currently fully known. There is good evidence however that Melanotan 
use carries some risk of cardiovascular disease and skin cancer (Evans-Brown 2009). 
How can we work with cosmetic drug users? 
 
There are several pieces of simple harm-reduction advice we can give to this group: 
 
• As far possible use reputable and medically trained professionals – if unable 
to access someone medically trained (for example a cosmetic doctor or plastic 
surgeon), make sure to seek out reliable reviews and testimonials on the service 
you are accessing, check if they have any training or qualifications, and ensure 
that their practice is clean and safe. Self-administering Botox or other cosmetic 
injections at home should be avoided as far as possible. 
 
• All standard safer-injecting advice given to other drug users would apply here, 
including always using clean needles, not sharing needles, avoiding blood 
vessels and nerves when injecting, using proper wound-care, and regularly 
screening for BBVs. 
 
• Be careful of counterfeit or mislabelled substances – this again can be 
avoided by only accessing services from medically trained professionals, but if 
self-administering be certain of what you are injecting and seek information and 
guidance on use beforehand. 
 
• If in doubt consult a medical professional, or if experiencing unexpected 
side effects seek medical attention 																																																								
5 Botox (botulinum toxin) itself is a prescription-only medicine and can only be obtained via a 
doctor or non-medical prescriber, but can be administered by anyone regardless of medical 
training. Despite this, more importantly there is a very wide range of other commonly used dermal 
fillers which are entirely unregulated. 
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Cosmetic drug users are unlikely to access traditional drug treatment or needle exchange 
services so drug services will need to be more proactive to engage users. Providing 
information at cosmetic surgeries and beautician services where users may seek cosmetic 
injections may be effective, however increasing use of these substances at home with 
substances ordered online makes some users particularly hard to engage. 
 
Due to the lack of firm research on habits of this group it is hard to speculate what other avenues 
of engagement may be most effective, however placing information at locations this group may 
be likely to visit may be the best approach in the absence of any better evidence – for example 
pharmacies, shops selling other beauty products, establishments providing other beauty 
treatments, or GPs clinics. 
 
 
Looking Forwards: Gender and social norms and IPEDs 
 
This documents has been primarily concerned with looking at IPEDs from the perspective of 
drugs services and other health services, concerned primarily with the health implications of use 
and how we can lessen these harms, with little discussion of the underlying motivations for us. 
The psychological and social reasons behind use should not be ignored in any form of 
problematic substance use, but for IPED dependency in particular it forms part of the core issue. 
Body Dysmorphic Disorder (in which individuals have an unrealistic perception of their 
musculature) resulting in dependent steroid use may be the more extreme end of such issues, 
however if we wish to address IPED use we need to also face these issues more widely and why 
individuals feel the need to pursue certain norms by these means.  
 
Fundamentally reasons for using Image and Performance Enhancing Drugs are grounded in how 
users perceive themselves, how they want others to perceive them, and social norms regarding 
how they are told they should look or achieve. Consequently, the issue of IPED use is 
inseparable from the wider cultural context and questions around social structures, social 
standing, self-worth, and mental health. Gender norms in particular appear significant in IPED 
use – it is no coincidence that steroid users are overwhelmingly male when steroids’ effects 
mirror masculine ideals of strength and size, nor that Botox users are overwhelmingly female 
when Botox effects mirror feminine ideals of smooth-skinned youth. 
 
Nevertheless, we should avoid patronisation or stigmatisation when talking about motivations for 
IPED use. Altering your appearance, being conscious of how you’re perceived, wishing to 
perform better, and subscribing to social norms are not unusual or necessarily dysfunctional 
behaviours, and nor are IPED users responsible for the existence of social norms and gender 
constructs. Pursuit of self-improvement is neither new nor unusual, by pharmaceutical means or 
otherwise. We can imagine that our reaction would likely be quite resistant if we were told that 
doing our hair in a certain way, wearing makeup, dressing in certain styles, going to the gym, 
getting piercings and tattoos, or pursuing certain diets were all a result of poor self-image and 
harmful social pressures. 
 
How we might challenge certain social norms (or indeed if we should) is far beyond the scope of 
this document, however If we wish to address the growing use of IPEDs in the UK, we cannot do 
so without at least beginning to question why people feel they need to change and culturally what 
are telling people they need to be.	 	
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